BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18173712)

  • 1. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma.
    Jiang F; Zhang X; Kalkanis SN; Zhang Z; Yang H; Katakowski M; Hong X; Zheng X; Zhu Z; Chopp M
    Photochem Photobiol; 2008; 84(1):128-37. PubMed ID: 18173712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
    Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
    Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using behavioral measurement to assess tumor progression and functional outcome after antiangiogenic treatment in mouse glioma models.
    Yang H; Chopp M; Zhang X; Jiang F; Zhang Z; Kalkanis S; Schallert T
    Behav Brain Res; 2007 Aug; 182(1):42-50. PubMed ID: 17572515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
    Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
    Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
    Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin reduces functional deficits caused by photodynamic therapy in rats.
    Zheng X; Chopp M; Lu Y; Jiang J; Zhao D; Ding C; Yang H; Zhang L; Jiang F
    Int J Oncol; 2011 Nov; 39(5):1133-41. PubMed ID: 21850369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model.
    Schmidt NO; Ziu M; Carrabba G; Giussani C; Bello L; Sun Y; Schmidt K; Albert M; Black PM; Carroll RS
    Clin Cancer Res; 2004 Feb; 10(4):1255-62. PubMed ID: 14977823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model.
    Diao Y; Tian XH; Huang YL; Chen LK; Lin XN; Zhuang ZW
    J Chemother; 2010 Dec; 22(6):407-12. PubMed ID: 21303749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
    Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of surgical resection and photodynamic therapy of 9L gliosarcoma in the nude rat.
    Zhang X; Jiang F; Kalkanis SN; Yang H; Zhang Z; Katakowski M; Hong X; Zheng X; Chopp M
    Photochem Photobiol; 2006; 82(6):1704-11. PubMed ID: 17007560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
    Wachsberger PR; Burd R; Marero N; Daskalakis C; Ryan A; McCue P; Dicker AP
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):835-42. PubMed ID: 15701874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-acute response of 9L gliosarcoma to Photofrin-mediated PDT in athymic nude mice.
    Zhang X; Jiang F; Kalkanis SN; Zhang Z; Hong X; Yang H; Chopp M
    Lasers Med Sci; 2007 Nov; 22(4):253-9. PubMed ID: 17505777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model.
    Yi D; Hua TX; Lin HY; Kui CL; Ning LX; Wang ZZ
    J Neurooncol; 2011 Aug; 104(1):93-101. PubMed ID: 21140283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.